NCT04172506

A Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid Tumors

A Multicenter, Open-label, Phase Ib/II Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid Tumors

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 65 (actual)
• Sponsor: Akeso · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a multi-center, multi-cohort, open-label, phase Ib/II study to evaluate the efficacy, safety, PK characteristics, immunogenicity and potential biomarkers of AK105 monotherapy in the patients with selected advanced solid tumors.

Conditions

• Solid Tumor
• Lung Cancer
• HCC

Interventions

Type	Name	Description
DRUG	AK105	Anti-PD-1 antibody

Timeline

• Start date: 2019-09-10
• Primary completion: 2021-12-01
• Completion: 2022-01-30
• First posted: 2019-11-21
• Last updated: 2025-03-12

Locations

1 site across 1 country: China

Regulatory

• FDA-regulated drug study